Abstract | AIM: PATIENTS AND METHODS: 94 patients with chronic heart failure of New York Heart Association (NYHA) class III-IV a left ventricular ejection fraction of 40% or less withanemia w ere idied in inveslain (58 males, 36 females). Anemia was detected when hemoglobin (b) was less than 120 g/l in males and less than in females. 46 patients received traditional treatment of CHF (I group) and 48 patients were treated additionally with erythropoietin (EPO) (II group). Percutaneous EPO 50 IU monthly to patients without iron deficiency for a period of 6 months. Echocardiography parameters, plasma NT and pro-BNP, cytokines, EPO, feritin and 6-minute walking test were assessed at baseline and after treatment. RESULT: in patients with CHF and anemia in II group erythropoietin treatment increased Hb levels by 22.4% (p < 0.05) and erythropoietin serum levels by 29.3 +/- 14.3 IU/ml (p < 0.001). Increased erythropoietin level was associated with decrease of cytokines levels: IL 1 by 36.6% (p < 0.001), IL 6 by 54.3% (p < 0.05), TNF alpha by 48.3% (p < 0.05) compared with patients in I group. In erythropoietin-treated patients there is a significant increase of LVEF by 19.04% (p < 0.05) compared with patients from I group. A greater 6-minute distance walked on exercise testing increased by 76.6% (p < 0.05) after treatment with erythropoieitin. CONCLUSIONS:
|
Authors | K Kh Zakhidova |
Journal | Vestnik Rossiiskoi akademii meditsinskikh nauk
(Vestn Ross Akad Med Nauk)
Issue 1-2
Pg. 32-7
( 2014)
ISSN: 0869-6047 [Print] Russia (Federation) |
PMID | 25055558
(Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)
|
Chemical References |
- Cytokines
- EPO protein, human
- Hemoglobins
- Interleukin-1
- Recombinant Proteins
- Tumor Necrosis Factor-alpha
- Erythropoietin
- Epoetin Alfa
|
Topics |
- Anemia
(blood, drug therapy, etiology)
- Chronic Disease
- Cytokines
(blood)
- Epoetin Alfa
- Erythropoietin
(blood, therapeutic use)
- Exercise Test
- Female
- Heart Failure
(blood, complications, drug therapy)
- Hemoglobins
(metabolism)
- Humans
- Interleukin-1
(blood)
- Male
- Middle Aged
- Recombinant Proteins
(therapeutic use)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(metabolism)
- Ventricular Function, Left
|